Product Development and Market Expansion - In 2026, the company plans to focus on high-end and intelligent iterations of its ventilator products, launching 1-2 flagship models with significant upgrades in safety and comfort features [2][3] - The company is actively preparing for international expansion, having completed a strategic stake in Rongxin Medical, which has a leading position in global respiratory health digital medical field, covering over 200 countries and regions [2][3] Strategic Partnerships and Product Launches - The collaboration with Philips focuses on core home health monitoring categories, including blood pressure, blood glucose, temperature, and blood oxygen monitoring, with products entering the market preparation phase [4] - Philips products will be positioned as high-end home medical devices, leveraging the company's e-commerce and retail networks for rapid market penetration [4] Hearing Business and Operational Efficiency - The hearing business showed steady growth in 2025, with improved operational efficiency and significant reduction in losses, laying a solid foundation for future profitability [5] - A new generation of bone conduction hearing aids, developed in collaboration with Tencent Cloud, was launched in November 2025, receiving positive market feedback and rapid sales growth [5] International Business Growth - In 2025, overseas business revenue reached approximately 300 million yuan, a year-on-year increase of over 400%, with products entering over 60 countries and regions [6] - The company is enhancing its B2B overseas business through strong customer relationships and ongoing product registration and certification processes [6] Core Product Growth and Marketing Strategy - The respiratory support segment saw an 80.18% year-on-year revenue increase in the second half of 2025, driven by the successful launch of self-developed smart connected ventilators [7] - The company plans to continue its focus on core products in 2026, optimizing marketing resources for targeted promotions while maintaining cost control [8] IPO Plans and Financing Strategy - The company has received approval for overseas issuance and is progressing with its Hong Kong IPO, aiming to enhance international brand influence and expand financing channels [9] - The dual listing strategy (A+H) is intended to provide stable capital support for R&D, capacity building, and global business expansion, enhancing risk resilience and sustainable development [9]
可孚医疗(301087) - 2026年3月9日投资者关系活动记录表